T. Rowe Price Investment Management Inc. Has $103.90 Million Holdings in Sotera Health (NASDAQ:SHC)

T. Rowe Price Investment Management Inc. decreased its position in shares of Sotera Health (NASDAQ:SHC - Free Report) by 19.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,594,741 shares of the company's stock after selling 1,823,250 shares during the quarter. T. Rowe Price Investment Management Inc. owned approximately 2.68% of Sotera Health worth $103,897,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD increased its position in shares of Sotera Health by 20.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 89,668 shares of the company's stock valued at $1,227,000 after buying an additional 15,156 shares in the last quarter. Khrom Capital Management LLC bought a new stake in shares of Sotera Health in the 4th quarter valued at $4,998,000. Tower Research Capital LLC TRC increased its position in shares of Sotera Health by 37.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,975 shares of the company's stock valued at $82,000 after buying an additional 1,640 shares in the last quarter. Voss Capital LP increased its position in shares of Sotera Health by 42.9% in the 4th quarter. Voss Capital LP now owns 500,000 shares of the company's stock valued at $6,840,000 after buying an additional 150,000 shares in the last quarter. Finally, MetLife Investment Management LLC increased its holdings in Sotera Health by 9.1% during the 4th quarter. MetLife Investment Management LLC now owns 86,177 shares of the company's stock worth $1,179,000 after purchasing an additional 7,174 shares in the last quarter. Institutional investors and hedge funds own 91.03% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on SHC shares. Piper Sandler lowered their target price on Sotera Health from $15.00 to $13.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. Barclays lowered their target price on Sotera Health from $16.00 to $12.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, Sotera Health currently has an average rating of "Moderate Buy" and an average target price of $15.20.

Sotera Health Stock Performance

NASDAQ SHC traded up $0.05 during trading on Tuesday, reaching $11.31. 725,146 shares of the company's stock were exchanged, compared to its average volume of 1,203,394. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. The business has a 50 day moving average price of $11.51 and a 200-day moving average price of $13.11. The stock has a market capitalization of $3.21 billion, a P/E ratio of 45.22 and a beta of 1.88. Sotera Health has a fifty-two week low of $9.53 and a fifty-two week high of $17.08.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.